胆碱酯酶抑制剂联合谷氨酸受体拮抗剂和降血脂药三联疗法治疗血管性痴呆的疗效观察及安全性评估

发布时间：2018-05-27 03:01

本文选题：血管性痴呆 + 联合用药　；参考：《兰州大学》2014年硕士论文

【摘要】：目的：对比探讨胆碱酯酶抑制剂联合谷氨酸受体拮抗剂、降血脂药三联疗法治疗血管性痴呆的临床疗效及安全评估。方法：将湖南省湘西自治州精神病医院康复中心2010年3月—2013年3月先后收治的60例血管性痴呆患者按用药不同分为对照组和治疗组各30例,其中治疗组在基础用药的基础上加用美金刚、阿托伐他汀和多奈哌齐；对照组加用多奈哌齐。两组共治疗6个月。两组治疗前后分别用简易精神认知量表(MMSE)、行为量表(Blessed-Roth)、日常生活能力量表(ADL)评定疗效；用药物副反应量表(TESS),相关实验室检查如血、尿、粪常规,心电图,肝、肾功能,电解质等指标评定用药安全性。结果：治疗后治疗组MMSE评分较对照组升高,ADL和Blessed-Roth评分较对照组降低,差异均有统计学意义(P0.05)。治疗组总有效率较对照组高(83.3%和53.3%),差异有统计学意义(x2=6.239,P0.05)。两组治疗后TESS评分比较差异无统计学意义(PO.05)。结论：胆碱酯酶抑制剂联合谷氨酸受体拮抗剂、降血脂药三联用药治疗血管性痴呆可以显著提高临床疗效,且联合用药不会影响其安全性。
[Abstract]:Objective: to evaluate the clinical efficacy and safety of cholinesterase inhibitor combined with glutamate receptor antagonist and antilipidemic drugs in the treatment of vascular dementia. Methods: sixty patients with vascular dementia were divided into control group (n = 30) and treatment group (n = 30) according to their medication from March 2010 to March 2013 in the Rehabilitation Center of Xiangxi Autonomous Prefecture Psychiatric Hospital of Hunan Province. The treatment group was treated with Atto vastatin and Donepezil on the basis of basic medication, while the control group with Donepezil. The two groups were treated for 6 months. Before and after treatment, the two groups were evaluated with MMSEN, Blessed-Rothia, ADL, and TESS with the drug side effects scale, including blood, urine, faecal routine, electrocardiogram, liver and kidney function. Electrolyte and other indicators were used to evaluate the safety of drug use. Results: after treatment, the MMSE scores in the treatment group were significantly higher than those in the control group, and the Blessed-Roth scores were significantly lower than those in the control group (P 0.05). The total effective rate of the treatment group was 83.3% and 53.3% higher than that of the control group, and the difference was statistically significant. There was no significant difference in TESS score between the two groups after treatment. Conclusion: cholinesterase inhibitor combined with glutamate receptor antagonist and triplex antilipidemic drugs can significantly improve the clinical efficacy of vascular dementia and its safety will not be affected by the combination of cholinesterase inhibitor and glutamate receptor antagonist.
【学位授予单位】：兰州大学
【学位级别】：硕士
【学位授予年份】：2014
【分类号】：R749.13

【参考文献】